Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, acco…
Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection. The findings also sugg…
WHAT: The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making s…
A fast test to diagnose fatal brain conditions such as mad cow disease in cattle and Creutzfeldt-Jakob disease in humans could be on the horizon, according to a new study from National Institutes of Health scientists. Researchers at NIH’s National I…
A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from …
History’s first recognized influenza pandemic originated in Asia and rapidly spread to other continents 500 years ago, in the summer of 1510. A new commentary by researchers at the National Institute of Allergy and Infectious Diseases, part of the…
Shoddy work by a DNA-repair enzyme allows tuberculosis-causing bacteria to develop antibiotic resistance, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have discovered. Reported in the current issue of the journal Cell, the finding could lead to new ways to treat TB without risking the development of drug resistance.
HHS Secretary Tommy G. Thompson today announced the award of two contracts totaling up to $20 million in first-year funding to develop safer smallpox vaccines. The three-year contracts were awarded to Bavarian Nordic A/S of Copenhagen, Denmark, and Acambis Inc. of Cambridge, Mass. The National Institute of Allergy and Infectious Diseases (NIAID) will administer the contracts.
A pivotal efficacy trial of an experimental vaccine designed to prevent genital herpes in women began enrolling volunteers this week. The study will determine the vaccine’s ability to prevent genital herpes disease in women who are free of two common types of herpes simplex viruses (HSV): HSV-1 and HSV-2. The trial will eventually enroll 7,550 women in at least 16 sites in the United States.
Clinical tests began today of a novel vaccine directed at the three most globally important HIV subtypes, or clades. Developed by scientists at the Dale and Betty Bumpers Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases, the vaccine incorporates HIV genetic material from clades A, B and C, which cause about 90 percent of all HIV infections around the world. “This is the first multigene, multiclade HIV vaccine to enter human trials,” said NIAID Director Anthony S. Fauci, M.D. “It marks an important milestone in our search for a single vaccine that targets U.S. subtypes of HIV as well as clades causing the global epidemic.”